David I Quinn Selected Research

Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)

12/2020	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
1/2018	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David I Quinn Research Topics

Disease

87	Neoplasms (Cancer) 02/2024 - 03/2003
68	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 02/2002
30	Renal Cell Carcinoma (Grawitz Tumor) 11/2023 - 10/2003
28	Carcinoma (Carcinomatosis) 01/2023 - 03/2003
16	Neoplasm Metastasis (Metastasis) 02/2024 - 03/2006
16	Urinary Bladder Neoplasms (Bladder Cancer) 10/2023 - 05/2005
10	Disease Progression 11/2022 - 08/2011
10	Pain (Aches) 01/2022 - 12/2008
9	Kidney Neoplasms (Kidney Cancer) 11/2023 - 10/2007
8	Circulating Neoplastic Cells 10/2022 - 04/2014
8	Fatigue 01/2022 - 10/2007
5	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 12/2021 - 06/2006
4	Transitional Cell Carcinoma 01/2021 - 09/2003
3	Bone Resorption 02/2024 - 04/2014
3	Hypertension (High Blood Pressure) 01/2022 - 03/2015
3	Fever (Fevers) 07/2017 - 10/2007
3	Exanthema (Rash) 09/2014 - 02/2012
3	Margins of Excision 01/2014 - 04/2003
2	Hyperphosphatemia 12/2020 - 01/2018
2	Nausea 02/2019 - 04/2015
2	Adrenocortical Carcinoma 01/2019 - 04/2015
2	Non-Muscle Invasive Bladder Neoplasms 07/2017 - 06/2017

Drug/Important Bio-Agent (IBA)

21	AndrogensIBA 03/2024 - 07/2003
19	Prostate-Specific Antigen (Semenogelase)IBA 03/2024 - 04/2003
17	Biomarkers (Surrogate Marker)IBA 02/2024 - 03/2003
14	Hormones (Hormone)IBA 03/2024 - 03/2003
14	Docetaxel (Taxotere)FDA Link 04/2020 - 02/2006
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2019 - 10/2003
12	PlatinumIBA 01/2022 - 10/2010
11	sipuleucel-T (APC8015)FDA Link 01/2023 - 08/2011
10	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 02/2009
8	Alkaline PhosphataseIBA 02/2024 - 08/2013
6	AntigensIBA 11/2022 - 03/2009
6	ErbB Receptors (EGF Receptor)IBA 10/2022 - 12/2009
6	pembrolizumabIBA 01/2022 - 01/2017
6	Tyrosine Kinase InhibitorsIBA 01/2022 - 12/2009
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2003
5	Immune Checkpoint InhibitorsIBA 10/2023 - 01/2021
5	LigandsIBA 01/2023 - 01/2017
5	Androgen Receptors (Androgen Receptor)IBA 01/2023 - 04/2005
5	Gemcitabine FDA Link 10/2019 - 12/2008
4	bicalutamide (Casodex)FDA LinkGeneric 03/2024 - 05/2015
4	orteronelIBA 03/2024 - 10/2022
4	Sunitinib (Sutent)FDA Link 10/2023 - 11/2018
4	infigratinibIBA 01/2022 - 01/2018
4	Prednisone (Sone)FDA LinkGeneric 10/2019 - 12/2008
4	Bevacizumab (Avastin)FDA Link 02/2019 - 07/2012
4	Sorafenib (BAY 43-9006)FDA Link 02/2019 - 01/2014
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2018 - 04/2006
4	Gonadotropin-Releasing Hormone (GnRH)FDA Link 12/2017 - 04/2013
3	collagen type I trimeric cross-linked peptideIBA 02/2024 - 04/2014
3	CollagenIBA 02/2024 - 04/2014
3	pyridinolineIBA 02/2024 - 04/2014
3	Messenger RNA (mRNA)IBA 01/2023 - 06/2005
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2023 - 12/2020
3	atezolizumabIBA 01/2023 - 01/2017
3	enfortumab vedotinIBA 01/2022 - 01/2020
3	Radium-223IBA 12/2019 - 06/2015
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2019 - 07/2012
3	CreatinineIBA 10/2019 - 01/2018
3	Hemoglobins (Hemoglobin)IBA 10/2019 - 04/2014
3	Phosphotransferases (Kinase)IBA 01/2019 - 11/2015
3	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2017 - 02/2009
3	AtrasentanIBA 01/2017 - 08/2013
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 12/2008
2	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 01/2014
2	Axitinib (AG 013736)IBA 10/2023 - 03/2015
2	Cell-Free Nucleic AcidsIBA 10/2023 - 01/2020
2	abirateroneIBA 01/2023 - 01/2019
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2022 - 12/2009
2	B7-H1 AntigenIBA 01/2022 - 01/2017
2	Histone Deacetylase InhibitorsIBA 01/2021 - 12/2017
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 12/2020
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 12/2020 - 01/2018
2	Monoclonal AntibodiesIBA 01/2020 - 06/2010
2	cixutumumabIBA 01/2020 - 05/2015
2	eribulin FDA Link 10/2019 - 11/2015
2	pazopanib FDA Link 02/2019 - 11/2018
2	Diphosphonates (Bisphosphonates)IBA 01/2019 - 08/2013
2	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2018 - 12/2008
2	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA 12/2017 - 12/2014
2	Interleukin-2 (IL2)IBA 12/2017 - 12/2005
2	lysine(6)-doxorubicin LHRHIBA 12/2017 - 12/2014
2	taxaneIBA 12/2017 - 12/2014
2	Carboplatin (JM8)FDA LinkGeneric 09/2017 - 12/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2017 - 03/2003
2	TOR Serine-Threonine KinasesIBA 07/2017 - 01/2016
2	cabazitaxel FDA Link 02/2017 - 10/2010

Therapy/Procedure

62	Therapeutics 03/2024 - 07/2003
41	Drug Therapy (Chemotherapy) 10/2023 - 05/2005
36	Castration 04/2023 - 03/2009
15	Prostatectomy (Retropubic Prostatectomy) 01/2021 - 02/2002
11	Cystectomy 10/2023 - 09/2003
11	Immunotherapy 01/2021 - 12/2011
8	Radiotherapy 01/2021 - 06/2004
5	Adjuvant Chemotherapy 12/2014 - 05/2005
4	Nephrectomy 10/2023 - 11/2018
4	Neoadjuvant Therapy 10/2023 - 12/2008
3	Aftercare (After-Treatment) 01/2023 - 05/2007
2	Salvage Therapy 01/2022 - 11/2003